Rafiq, Nila

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)

Golabi, P., Otgonsuren, M., de Avila, L., Sayiner, M., Rafiq, N., & Younossi, Z. M. (2018) · Medicine

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 221

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)

Golabi, P., Stepanova, M., Pham, H. T., Cable, R., Rafiq, N., Bush, H., Gogoll, T., & Younossi, Z. M. (2018) · BMJ Open Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 32